| 2.38 0.18 (8.18%) | 04-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.52 | 1-year : | 10.86 |
| Resists | First : | 6.44 | Second : | 9.29 |
| Pivot price | 5.08  |
|||
| Supports | First : | 1.81 | Second : | 1.51 |
| MAs | MA(5) : | 2.16  |
MA(20) : | 5.64 |
| MA(100) : | 6.74 |
MA(250) : | 4.55 |
|
| MACD | MACD : | -1.7 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 5.4 |
D(3) : | 4.4 |
| RSI | RSI(14): 28.5 |
|||
| 52-week | High : | 12.36 | Low : | 1.81 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LPCN ] has closed above bottom band by 26.0%. Bollinger Bands are 231.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.46 - 2.47 | 2.47 - 2.48 |
| Low: | 2.12 - 2.13 | 2.13 - 2.14 |
| Close: | 2.36 - 2.38 | 2.38 - 2.39 |
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.
Tue, 07 Apr 2026
Higuchi John W. buys Lipocine (LPCN) shares worth $81199 - Investing.com
Tue, 07 Apr 2026
Director John Higuchi adds 40,000 Lipocine (LPCN) shares at $2.03 - Stock Titan
Thu, 02 Apr 2026
Phase 3 PPD trial for Lipocine (NASDAQ: LPCN) drug falls short - Stock Titan
Thu, 02 Apr 2026
[8-K] Lipocine Inc. Reports Material Event - Stock Titan
Thu, 02 Apr 2026
Lipocine stock tumbles after phase 3 trial misses endpoint - Investing.com
Thu, 02 Apr 2026
Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 2.1 (%) |
| Held by Institutions | 22.3 (%) |
| Shares Short | 152 (K) |
| Shares Short P.Month | 127 (K) |
| EPS | -1.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.34 |
| Profit Margin | 0 % |
| Operating Margin | -219.7 % |
| Return on Assets (ttm) | -32.9 % |
| Return on Equity (ttm) | -54.3 % |
| Qtrly Rev. Growth | -67.2 % |
| Gross Profit (p.s.) | 0.27 |
| Sales Per Share | 0.27 |
| EBITDA (p.s.) | -1.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -1.35 |
| PEG Ratio | 0 |
| Price to Book value | 1.01 |
| Price to Sales | 8.77 |
| Price to Cash Flow | -1.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|